PA
ADVM

Pinnacle Associates’s Adverum Biotechnologies ADVM Stock Holding History

Pinnacle Associates’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,196
Closed -$512K – 765
2021
Q1 		$512K Sell
5,196
-30
-0.6% -$3.6K 0.01% 525
2020
Q4 		$566K Buy
5,226
+55
+1% +$6.8K 0.01% 493
2020
Q3 		$533K Buy
5,171
+320
+7% +$47.9K 0.01% 482
2020
Q2 		$1.01M Buy
+4,851
New +$859K 0.03% 360

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pinnacle Associates's ADVM Position: Q2 2021 in Review

Pinnacle Associates sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 5,196 shares — an estimated $512K sold.

Pinnacle Associates first reported a position in ADVM in Q2 2020 and held it in 4 quarters. The position peaked at $1.01M in Q2 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Pinnacle Associates reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Pinnacle Associates sold 5,196 Adverum Biotechnologies shares in Q2 2021, an estimated $512K.
  • Pinnacle Associates first reported a position in Adverum Biotechnologies in Q2 2020 and held it in 4 quarters.
  • Pinnacle Associates's Adverum Biotechnologies position peaked at $1.01M in Q2 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Pinnacle Associates's 13F filing for Q2 2021, filed 2 Aug 2021.